Impact of Dissection after Drug-Coated Balloon Treatment of De Novo Coronary Lesions: Angiographic and Clinical Outcomes

PurposeDissection after plain balloon angioplasty is required to achieve adequate luminal area; however, it is associated with a high risk of vascular events. This study aimed to examine the relationship between non-flow limiting coronary dissections and subsequent lumen loss and long-term clinical outcomes following successful drug-coated balloon (DCB) treatment of de novo coronary lesions.Materials and MethodsA total of 227 patients with good distal flow (Thrombolysis in Myocardial Infarction flow grade 3) following DCB treatment were retrospectively enrolled and stratified according to the presence or absence of a non-flow limiting dissection. The primary endpoint was late lumen loss (LLL) at 6-month angiography, and the secondary endpoint was target vessel failure (TVF, a composite of cardiac death, target vessel myocardial infarction, target vessel revascularization, and target vessel thrombosis).ResultsThe cohort consisted of 95 patients with and 132 patients without a dissection. There were no between-group differences in LLL (90.8%) returning for angiography at 6 months (0.05±0.19 mm in non-dissection and 0.05±0.30 mm in dissection group, p=0.886) or in TVF (6.8% in non-dissection and 8.4% in dissection group, p=0.799) at a median follow-up of 3.4 years. In a multivariate analysis, the presence of dissection and its severity were not associated with LLL or TVF. Almost dissections (93.9%) were completely healed, and there was no newly developed dissection at 6-month angiography.ConclusionThe presence of a dissection following successful DCB treatment of a de novo coronary lesion may not be associated with an increased risk of LLL or TVF (Impact of Drug-coated Balloon Treatment in de Novo Coronary Lesion; {"type":"clinical-trial","attrs":{"text":"NCT04619277","term_id":"NCT04619277"}}NCT04619277).     

纳洛酮抢救海洛因中毒618例临床分析

目的：观察纳洛酮抢救海洛因中毒的疗效。方法：对618例海洛因中毒患,用纳洛酮抢救,首次剂量给纳洛酮针剂0．4－0．8mg静注,然后以0．4mg每5min1次,直到患清醒后再给0．8－1．2mg维持静滴。结果：618例中死亡9例,抢救成功率达98％。结论：纳洛酮是抢救海洛因中毒的理想特效药。     

肾综合症出血热血清蛋白与肝肾功能及临床关系的研究

目的 了解肾综合症出血热（HFRS）各期血清蛋白的变化特点及其与肝、肾功能的关系。方法 采用瑞士产COBAS MIRA PLUS CC全血动生化分析仪及日本产MA－4210尿液分析仪分别检测同时的空腹静脉血及晨尿。结果 150例HFRS患者217次检测血清总蛋白（T）平均为63.51g/L,白蛋白（A）为36.29g/L,球蛋白（G）为27.22g/L,A/G=1.33。其中A／G为1.49-1.0者137例（63.3%）,A／G＜1.0者27例（12.44%）,A／G≥1.5者53例（24.42%）。结论 HFRS患者有75.58%存在着低白蛋白血症,并贯穿于各期,异常程度与病情轻重呈正相关,主要原因是肾脏损害,大量白蛋白从尿中丢失,与肝脏的合成功能关系不大。     

东方田鼠室内繁殖与生长发育观察

近年来,逐渐增多的小鼠突变系资源已对现有的动物设施和品种（系）的保存方法提出严峻的挑战,小鼠胚胎和配合子的低温保存是目前保存小鼠种群资源中应用最为广泛的方法,通过低温保存不仅使原有的或新开发的小鼠品系得以安全的,长期的保存下来,同时也使这些小 模型的规模化生产,推广普及变得更为简单化,无疑,小鼠模型的保存将为21世纪哺乳类遗传学的飞速发展和最终攻克人类目前的疑难疾病创造了有利条件。     

真空紫外辐照对加成型硅橡胶光学性能的影响

考察了加成型硅橡胶在真空环境中经1000ESH紫外辐照后的性能变化。结果表明,辐照后材料均出现发黄的现象,光学透过率大幅度 下降,同时加入硅酸钾包覆后制备的热控涂层反射率下降。经原位测试与离位测试,发现加成型硅橡胶在两种不同条件下测得的结果差异较小,而在有机硅橡胶中加入ZnO后原位与离位测试结果则差异明显,表现出明显的漂白作用。     

Analysis of the factors influencing the therapeutic effects of onychomycosis

From July 1 994to June 1 999,5 4 5 onychomyco-sis patients were treated with Itraconazole and com-pleted their treatment courses with complete follow-up in out- patientdepartment.The recovery rate was83.1 4% and 79.2 3% in fingernail and toenail dis-eases respectively.But following phenomena werefound:( 1 ) Some new nails stopped growing in cer-tain length,even if the treatment continued;( 2 )Some damaged nails reappeared soon after the treat-ment ceased;( 3) Some damaged nails with deep- co…     

Long non-coding RNA LINC01116 accelerates the progression of keloid formation by regulating miR-203/SMAD5 axis

BackgroundEmerging evidence reveals the importance of long non-coding RNAs (lncRNAs) in the development and progression of keloid formation. However, the roles and molecular mechanism of lncRNA LINC01116 in the progression of keloid formation remain largely unknown.MethodsThe expression levels of LINC01116, microRNA-203 (miR-203) and SMAD family member 5 (SMAD5) were measured by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. Cell proliferation, migration and invasion were detected by Cell counting Kit-8 (CCK-8) assay and transwell assay. Flow cytometry and western blot assay were used to examine cell apoptosis and extracellular matrix (ECM) production. The interaction between miR-203 and LINC01116 or SMAD5 was predicted by bioinformatics analysis and verified by dual-luciferase reporter and RNA Immunoprecipitation (RIP) and RNA pull-down assays.ResultsLINC01116 and SMAD5 were upregulated while miR-203 was downregulated in keloid tissues and keloid fibroblasts. LINC01116 knockdown suppressed the proliferation, migration, invasion, and ECM production but induced apoptosis in keloid fibroblasts through enhancing miR-203 and inhibiting SMAD5. Moreover, SMAD5 was identified as a direct target of miR-203 and miR-203 could directly bind to LINC01116. Besides, LINC01116 regulated SMAD5 expression by targeting miR-203.ConclusionDownregulation of LINC01116 inhibited the progression of keloid formation by regulating miR-203/SMAD5 axis, which might provide a novel target for keloid therapy.     

Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019

BackgroundSevere acute respiratory syndrome (SARS) and coronavirus disease 2019 (COVID-19) are closely related. The effect of AKI on the clinical outcomes of these two conditions is unclear.MethodsThis retrospective, territory-wide cohort study used an electronic public healthcare database in Hong Kong to identify patients with SARS or COVID-19 by diagnosis codes, virologic results, or both. The primary endpoint was a composite of intensive care unit admission, use of invasive mechanical ventilation, and/or death.ResultsWe identified 1670 patients with SARS and 1040 patients with COVID-19 (median ages, 41 versus 35 years, respectively). Among patients with SARS, 26% met the primary endpoint versus 5.3% of those with COVID-19. Diabetes mellitus, abnormal liver function, and AKI were factors significantly associated with the primary endpoint among patients with either SARS or COVID-19. Among patients with SARS, 7.9%, 2.1%, and 3.7% developed stage 1, stage 2, and stage 3 AKI, respectively; among those with COVID-19, 6.6%, 0.4%, and 1.1% developed stage 1, stage 2, and stage 3 AKI, respectively. In both groups, factors significantly associated with AKI included diabetes mellitus and hypertension. Among patients with AKI, those with COVID-19 had a lower rate of major adverse clinical outcomes versus patients with SARS. Renal function recovery usually occurred within 30 days after an initial AKI event.ConclusionsAKI rates were higher among patients with SARS than those with COVID-19. AKI was associated with major adverse clinical outcomes for both diseases. Patients with diabetes mellitus and abnormal liver function were also at risk of developing severe consequences after SARS and COVID-19 infection.     

The New Normal? Patient Satisfaction and Usability of Telemedicine in Breast Cancer Care

Annals of Surgical Oncology - Telemedicine was adopted to minimize exposure risks for patients and staff during the coronavirus disease 2019 pandemic. This study measured patient satisfaction and...     

Double hernia in continuous ambulatory peritoneal dialysis patient

Clinical and Experimental Nephrology -